Tumor biomarkers: association with heart failure outcomes

Shi, C. et al. (2020) Tumor biomarkers: association with heart failure outcomes. Journal of Internal Medicine, 288(2), pp. 207-218. (doi: 10.1111/joim.13053) (PMID:32372544)

214416.pdf - Published Version
Available under License Creative Commons Attribution.



Background: There is increasing recognition that heart failure (HF) and cancer are conditions with a number of shared characteristics. Objectives: To explore the association between tumour biomarkers and HF outcomes. Methods: In 2,079 patients of BIOSTAT‐CHF cohort, we measured six established tumour biomarkers: CA125, CA15‐3, CA19‐9, CEA, CYFRA 21‐1 and AFP. Results: During a median follow‐up of 21 months, 555 (27%) patients reached the primary end‐point of all‐cause mortality. CA125, CYFRA 21‐1, CEA and CA19‐9 levels were positively correlated with NT‐proBNP quartiles (all P < 0.001, P for trend < 0.001) and were, respectively, associated with a hazard ratio of 1.17 (95% CI 1.12–1.23; P < 0.0001), 1.45 (95% CI 1.30–1.61; P < 0.0001), 1.19 (95% CI 1.09–1.30; P = 0.006) and 1.10 (95% CI 1.05–1.16; P < 0.001) for all‐cause mortality after correction for BIOSTAT risk model (age, BUN, NT‐proBNP, haemoglobin and beta blocker). All tumour biomarkers (except AFP) had significant associations with secondary end‐points (composite of all‐cause mortality and HF hospitalization, HF hospitalization, cardiovascular (CV) mortality and non‐CV mortality). ROC curves showed the AUC of CYFRA 21‐1 (0.64) had a noninferior AUC compared with NT‐proBNP (0.68) for all‐cause mortality (P = 0.08). A combination of CYFRA 21‐1 and NT‐proBNP (AUC = 0.71) improved the predictive value of the model for all‐cause mortality (P = 0.0002 compared with NT‐proBNP). Conclusions: Several established tumour biomarkers showed independent associations with indices of severity of HF and independent prognostic value for HF outcomes. This demonstrates that pathophysiological pathways sensed by these tumour biomarkers are also dysregulated in HF.

Item Type:Articles
Additional Information:Canxia Shi is supported with a scholarship from the China Scholarship Council [CSC number: 201806170057]. Dr de Boer is furthermore supported by the Dutch Heart Foundation [CVON DOSIS, grant 2014-40, CVON 19 SHE-PREDICTS-HF, grant 2017-21; CVON RED-CVD, grant 2017-11; and CVON PREDICT2, grant 2018-30]; and the Innovational Research Incentives Scheme program of the Netherlands Organization for Scientific Research [NWO VIDI, grant 917·13·350], and by a grant from the Leducq Foundation [Cure PhosphoLambaN induced Cardiomyopathy (CurePLaN)].
Glasgow Author(s) Enlighten ID:Cleland, Professor John
Authors: Shi, C., van der Wal, H. H., Silljé, H. H.W., Dokter, M. M., van den Berg, F., Huizinga, L., Vriesema, M., Post, J., Anker, S. D., Cleland, J. G., Ng, L. L., Samani, N. J., Dickstein, K., Zannad, F., Lang, C. C., van Haelst, P. L., Gietema, J. A., Metra, M., Ameri, P., Canepa, M., van Veldhuisen, D. J., Voors, A. A., and de Boer, R. A.
College/School:College of Medical Veterinary and Life Sciences > Institute of Health and Wellbeing > Robertson Centre
Journal Name:Journal of Internal Medicine
ISSN (Online):1365-2796
Published Online:05 May 2020
Copyright Holders:Copyright © 2020 The Authors
First Published:First published in Journal of Internal Medicine 288(2): 207-218
Publisher Policy:Reproduced under a Creative Commons License

University Staff: Request a correction | Enlighten Editors: Update this record